Tazorac (tazarotene) NDC 16110-042

NDC codes

FDA NDC Directory

Product NDC (as listed)16110-042Labeler and product segments. Claims need a package NDC.

Product NDC at billing width16110-0042Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
16110-042-10	16110004210	1 TUBE in 1 CARTON (16110-042-10) / 100 g in 1 TUBEMarketed from Feb 21, 2020
16110-042-30	16110004230	1 TUBE in 1 CARTON (16110-042-30) / 30 g in 1 TUBEMarketed from Feb 21, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tazorac
Generic name (nonproprietary): tazarotene
Active ingredients: Tazarotene — 1 mg/g
Dosage form: Gel
Route: Cutaneous
Labeler: Almirall, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 020600
Marketing start: Feb 21, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Retinoids (Chemical structure)
Identifiers: Product ID 16110-042_7e6df473-8f69-4d67-bd06-a24f35ab0a62SPL ID 7e6df473-8f69-4d67-bd06-a24f35ab0a62SPL set ID 4e4e4b81-420e-4492-8a74-80b692a80057RxCUI 212437, 212438, 313199, 313201UNII 81BDR9Y8PSUPC 0316110042107, 0316110042305, 0316110833309, 0316110833101
Pharmacologic class: Retinoid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N416110004210 followed by a unit qualifier and the quantity

Package 16110-0042-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 13, 2025.

Indications (excerpt from the label)

TAZORAC ® Gel, 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement. ( 1.1 ) TAZORAC Gel, 0.1% is indicated for the topical treatment of mild to moderate facial acne vulgaris. ( 1.2 ) Limitations of Use The safety of TAZORAC Gel use on more than 20% body surface area has not been established. ( 1.3 ) 1.1 Plaque Psoriasis TAZORAC® (tazarotene) Gel, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis of up to 20% body surface area involvement. 1.2 Acne Vulgaris TAZORAC (tazarotene) Gel, 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 020600

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 020600
Product	Strength	Form · route	Labeler	Product NDC
Tazoractazarotene	Tazarotene .5 mg/g	GelCutaneous	Almirall, LLC	16110-833